Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,000
Closed -$133K – 11144
2026
Q2
$133K Buy
+1,000
New +$113K ﹤0.01% 7022

Other funds holding ABVX

UBS Group's ABVX Position: Q3 2026 in Review

UBS Group reduced its Abivax (ABVX) stake by 79% in Q3 2026, selling an estimated $177M and leaving 380,365 shares worth $37.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1980.

UBS Group first reported a position in ABVX in Q1 2024 and has held it in 10 quarters since. The position peaked at $597M in Q4 2025. 319 funds tracked by Wall St. Rank hold ABVX as of Q3 2026.

  • UBS Group held 380,365 shares of Abivax worth $37.7M as of Q3 2026.
  • UBS Group sold 1,464,553 Abivax shares in Q3 2026, an estimated $177M.
  • Abivax made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #1980 holding.
  • UBS Group first reported a position in Abivax in Q1 2024 and has held it in 10 quarters since.
  • UBS Group's Abivax position peaked at $597M in Q4 2025.
  • 319 funds tracked by Wall St. Rank held Abivax as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.